Clinical trial NCT04631848: ULTRASCORE™ Focused Force PTA Balloon Angioplasty for CLI Patients With Below the Knee Vessel Disease
Official title: ULTRASCORE™ Focused Force PTA Balloon Angioplasty for CLI Patients With Below the Knee Vessel Disease- a Multi-center Experience in 80 Subsequent Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Peripheral Arterial Disease (PAD)
Keywords: Scoring balloon dilatation
Lead sponsor: Klinikum Arnsberg
Sponsor class: OTHER
First posted: 2020-11-17
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients from clinics with vascular centers

Brief summary: The purpose of this single-arm, exploratory study is to evaluate safety and performance of treatment of critical limb ischemia (CLI) with the ULTRASCORE™ Focused Force balloon.

Patients with CLI in below the knee vessels will receive a percutaneous transluminal angioplasty with the device and will be followed up for 12 months.

Detailed description: This single-arm, prospective, multi-center CE marked study (IIT) is planned to include up to 80 subjects with CLI in below the knee vessels with de novo stenoses or non-stented re-stenotic in total greater or equal 70% stenosis or occlusion of lower limb lesion. During the index procedure at Day 1 patients will be treated with ULTRASCORE™ Focused Force balloon.

Follow-up investigations for evaluation of parameters for primary and secondary endpoints will be performed at 4 weeks, 6 months, and 12 months after the index procedure..

Eligibility criteria: Inclusion Criteria:

1. Patients must be ≥ 18 years of age.
2. Patients are male or, if female, are either not of childbearing potential or must have a negative pregnancy test done within 7 days prior-index procedure and effective contraception must be used during participation in the Clinical Investigation.
3. Patients who are mentally and linguistically able to understand the aim of the Clinical Investigation and to show sufficient compliance in following the Clinical Investigation Plan.
4. Patients must agree to return for all required post-index procedure follow-up visits.
5. Patients are able to verbally acknowledge an understanding of the associated risks, benefits, and treatment alternatives to therapeutic options of the Clinical Investigation. Patients, by providing their informed consent, agree to these risks and benefits as stated in the patient informed consent document.
6. Rutherford Class 4-5
7. ≥70% stenosis of lower limb lesion by angio visual assessment
8. Target vessel(s) reconstitute(s) at or above the ankle with inline flow to at least one patent pedal vessel (includes perforating peroneal branches to dorsalis pedis and plantar artery).
9. The target lesion must either be de-novo or re-stenotic (stenosis ≥ 70% or occlusion by visual estimate). If the target lesion is re-stenotic, the prior PTA must have been done \> 30 days prior-index procedure.
10. Treatment of multiple target lesions is allowed, as long as the composite target lesion length is ≤ 30 cm
11. At least one target lesion that is ≥ 2cm in length

Exclusion Criteria:

1. Patients with a known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, or other anticoagulant/anti-platelet therapies, Paclitaxel (or analogs) or sensitivity to contrast media that cannot be adequately premedicated.
2. Patients with any contraindications as mentioned in the Instructions for Use (IFU) of the Investigational Device.
3. Patients with a life expectancy, from the Investigator's opinion, of less than 2 years.
4. Patients that are currently participating in other clinical investigations involving any investigational drug or device that may potentially confound the results of the Clinical Investigation, or that would limit the patient's compliance with the follow-up requirements of the Clinical Investigation.
5. Patients with a history of Myocardial Infarction (MI), thrombolysis or angina within 30 days prior-index procedure.
6. Patients with a history of major disabling stroke within 3 months prior index procedure.
7. Patients with a presence or history of severe renal failure (Glomerular Filtration Rate (GFR) ≤ 25 ml/min).
8. Patients who have undergone prior vascular surgery of the index limb to treat atherosclerotic disease.
9. Patients with clinically significant aneurysmal disease of the iliac, femoral or popliteal artery and patients with a history of clinically significant abdominal aortic aneurysm.
10. Target vessel(s) reconstitute(s) below the ankle with no inline flow to at least one patent pedal vessel.
11. Subjects scheduled to undergo a planned major amputation

Primary outcomes:
measure: Number of patients with patency of target lesion
timeFrame: 12 months
measure: Number of patients with composite safety
timeFrame: 4 weeks
Secondary outcomes:
measure: Number of patients with patency measured with PSVR
timeFrame: 1, 6 and 12 months
measure: Number of patients with secondary patency
timeFrame: 6 and 12 months
measure: Number of patients with MAE (major adverse events) and MALE (Major adverse limb events)
timeFrame: 1 , 6 and 12 months
measure: Number of patients with procedural success
timeFrame: Day 1 after the index procedure
measure: Number of patients with Device Success
timeFrame: Day 1 post Ultrascore usage
measure: Ankle-Brachial Index (ABI)
timeFrame: 6 and 12 months
measure: Number of patients with Clinical success
timeFrame: 6 and 12 months
measure: Number of patients with freedom from Target Lesion Revascularisation (TLR)
timeFrame: 6 and 12 months
measure: Number of patients with freedom from Target Vessel Revascularisation (TVR)
timeFrame: 6 and 12 months
measure: Number of patients with freedom from minor amputation
timeFrame: 6 and 12 months
measure: Comparison of pain rating scale scores to Baseline
timeFrame: 6 and 12 months
measure: Comparison of the scores on the Walking Impairment Questionnaire (WIQ) to Baseline
timeFrame: 6 and 12 months
Other outcomes:
Locations:
city: Arnsberg
country: Germany
facility: Klinikum Hochsauerland, Karolinen-Hospital
Study officials:
affiliation: Klinikum Hochsauerland GmbH
name: Michael Lichtenberg, Dr. med.
role: PRINCIPAL_INVESTIGATOR
References: